Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD).
Background:
t-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress.
Materials and methods:
We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20–30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed.
Results:
The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events.
Conclusions:
t-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
Get full access to this article
View all access options for this article.
References
1.
. KesslerRC, PetukhovaM, SampsonNA, ZaslavskyAM, WittchenH-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res, 2012; 21:169–184.
2.
. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl, 2016; 388:1545–1602.
3.
. BloomDE, CafieroE, Jané-LlopisE, et al.The Global Economic Burden of Noncommunicable Diseases. Program on the Global Demography of Aging. 2012. Available at: https://ideas.repec.org/p/gdm/wpaper/8712.html (Last accessed July11, 2018).
4.
. van BeljouwI, VerhaakP, PrinsM, CuijpersP, PenninxB, BensingJ. Reasons and determinants for not receiving treatment for common mental disorders. Psychiatr Serv, 2010; 61:250–257.
5.
. BarrettB, ByfordS, KnappM. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord, 2005; 84:1–13.
6.
. JormAF, GriffithsKM, ChristensenH, ParslowRA, RogersB. Actions taken to cope with depression at different levels of severity: a community survey. Psychol Med, 2004; 34:293–299.
7.
. CassanoP, FavaM. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry, 2004; 16:15–25.
8.
. KennedySH, LamRW, McIntyreRS, et al.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry, 2016; 61:540–560.
9.
. ParikhSV, QuiltyLC, RavitzP, et al.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. Can J Psychiatry, 2016; 61:524–539.
10.
. MilevRV, GiacobbeP, KennedySH, et al.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatry, 2016; 61:561–575.
11.
. MohammedHS.Transcranial low-level infrared laser irradiation ameliorates depression induced by reserpine in rats. Lasers Med Sci, 2016; 31:1651–1656.
12.
. SalehpourF, RastaSH. The potential of transcranial photobiomodulation therapy for treatment of major depressive disorder. Rev Neurosci, 2017; 28:441–453.
13.
. SalehpourF, RastaSH, MohaddesG, Sadigh-EteghadS, SalariradS. Therapeutic effects of 10-Hz pulsed wave lasers in rat depression model: a comparison between near-infrared and red wavelengths. Lasers Surg Med, 2016; 48:695–705.
14.
. XuZ, GuoX, YangY, et al.Low-level laser irradiation improves depression-like behaviors in mice. Mol Neurobiol, 2017; 54:4551–4559.
15.
. WuX, AlbericoSL, MogesH, De TaboadaL, TedfordCE, AndersJJ. Pulsed light irradiation improves behavioral outcome in a rat model of chronic mild stress. Lasers Surg Med, 2012; 44:227–232.
16.
. SchifferF, JohnstonAL, RavichandranC, et al.Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct, 2009; 5:46.
17.
. CassanoP, PetrieSR, HamblinMR, HendersonTA, IosifescuDV. Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. Neurophotonics, 2016; 3:031404.
18.
. CassanoP, CusinC, MischoulonD, et al.Near-infrared transcranial radiation for major depressive disorder: proof of concept study. Psychiatry J, 2015; 2015:352979.
19.
. CaldieraroMA, SaniG, BuiE, CassanoP. Long-term near-infrared photobiomodulation for anxious depression complicated by Takotsubo cardiomyopathy. J Clin Psychopharmacol, 2018; 38:268–270.
20.
. Mirzaii-DizgahI, OjaghiR, SadeghipourHR, Sadeghipour-RoodsariHR, KarimianSM, SohanakiH. Attenuation of morphine withdrawal signs by low level laser therapy in rats. Behav Brain Res, 2009; 196:268–270.
21.
. HagiwaraS, IwasakaH, HasegawaA, NoguchiT. Pre-irradiation of blood by gallium aluminum arsenide (830 nm) low-level laser enhances peripheral endogenous opioid analgesia in rats. Anesth Analg, 2008; 107:1058–1063.
22.
. ChungH, DaiT, SharmaSK, HuangY-Y, CarrollJD, HamblinMR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng, 2012; 40:516–533.
23.
. YuW, NaimJO, McGowanM, IppolitoK, LanzafameRJ. Photomodulation of oxidative metabolism and electron chain enzymes in rat liver mitochondria. Photochem Photobiol, 1997; 66:866–871.
24.
. OronU, IlicS, De TaboadaL, StreeterJ. Ga-As (808 nm) laser irradiation enhances ATP production in human neuronal cells in culture. Photomed Laser Surg, 2007; 25:180–182.
25.
. Mochizuki-OdaN, KataokaY, CuiY, YamadaH, HeyaM, AwazuK. Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue. Neurosci Lett, 2002; 323:207–210.
26.
. Zalewska-KaszubskaJ, ObzejtaD. Use of low-energy laser as adjunct treatment of alcohol addiction. Lasers Med Sci, 2004; 19:100–104.
27.
. JagdeoJR, AdamsLE, BrodyNI, SiegelDM. Transcranial red and near infrared light transmission in a cadaveric model. PLoS One, 2012; 7:e47460.
28.
. TedfordCE, DeLappS, JacquesS, AndersJ. Quantitative analysis of transcranial and intraparenchymal light penetration in human cadaver brain tissue. Lasers Surg Med, 2015; 47:312–322.
29.
. HendersonTA, MorriesLD. Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?. Neuropsychiatr Dis Treat, 2015; 11:2191–2208.
. ChaiebL, AntalA, MasuratF, PaulusW. Neuroplastic effects of transcranial near-infrared stimulation (tNIRS) on the motor cortex. Front Behav Neurosci, 2015; 9:147.
32.
. HendersonTA, MorriesLD. SPECT perfusion imaging demonstrates improvement of traumatic brain injury with transcranial near-infrared laser phototherapy. Adv Mind Body Med, 2015; 29:27–33.
33.
. NawashiroH, WadaK, NakaiK, SatoS. Focal increase in cerebral blood flow after treatment with near-infrared light to the forehead in a patient in a persistent vegetative state. Photomed Laser Surg, 2012; 30:231–233.
34.
. SalgadoASI, ZângaroRA, ParreiraRB, KerppersII. The effects of transcranial LED therapy (TCLT) on cerebral blood flow in the elderly women. Lasers Med Sci, 2015; 30:339–346.
. BarrettDW, Gonzalez-LimaF. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. Neuroscience, 2013; 230:13–23.
37.
. BlancoNJ, MaddoxWT, Gonzalez-LimaF. Improving executive function using transcranial infrared laser stimulation. J Neuropsychol, 2017; 11:14–25.
38.
. HwangJ, CastelliDM, Gonzalez-LimaF. Cognitive enhancement by transcranial laser stimulation and acute aerobic exercise. Lasers Med Sci, 2016; 31:1151–1160.
39.
. NaeserMA, ZafonteR, KrengelMH, et al.Significant improvements in cognitive performance post-transcranial, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury: open-protocol study. J Neurotrauma, 2014; 31:1008–1017.
40.
. NaeserMA, SaltmarcheA, KrengelMH, HamblinMR, KnightJA. Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomed Laser Surg, 2011; 29:351–358.
41.
. MorriesLD, CassanoP, HendersonTA. Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy. Neuropsychiatr Dis Treat, 2015; 11:2159–2175.
42.
. HackeW, SchellingerPD, AlbersGW, et al.Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke J Cereb Circ, 2014; 45:3187–3193.
43.
. LamplY, ZivinJA, FisherM, et al.Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke J Cereb Circ, 2007; 38:1843–1849.
44.
. ZivinJA, AlbersGW, BornsteinN, et al.Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke, 2009; 40:1359–1364.
45.
. Jöbsis-VanderVlietFF, PiantadosiCA, SylviaAL, LucasSK, KeizerHH. Near-infrared monitoring of cerebral oxygen sufficiency. I. Spectra of cytochrome c oxidase. Neurol Res, 1988; 10:7–17.
. TargumSD, BusnerJ, YoungAH. Targeted scoring criteria reduce variance in global impressions. Hum Psychopharmacol, 2008; 23:629–633.
48.
. RushAJ, TrivediMH, IbrahimHM, et al.The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry, 2003; 54:573–583.
49.
. Liu-SeifertH, ZhangS, D'SouzaD, SkljarevskiV. A closer look at the baseline-observation-carried-forward (BOCF). Patient Prefer Adherence, 2010; 4:11–16.
50.
. WoolleySB, CardoniAA, GoetheJW. Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies. Pharmacotherapy, 2009; 29:1408–1416.
51.
. HendersonT, MorriesL. Multi-watt near-infrared phototherapy for the treatment of comorbid depression: an open-label single-arm study. Front Psychiatry, 2017; 8:187.
52.
. DisnerSG, BeeversCG, Gonzalez-LimaF. Transcranial laser stimulation as neuroenhancement for attention bias modification in adults with elevated depression symptoms. Brain Stimulat, 2016; 9:780–787.
53.
. MooreCM, ChristensenJD, LaferB, FavaM, RenshawPF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry, 1997; 154:116–118.
54.
. VolzHP, RzannyR, RiehemannS, et al.31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci, 1998; 248:289–295.
55.
. RenshawPF, ParowAM, HirashimaF, et al.Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry, 2001; 158:2048–2055.
56.
. IosifescuDV, BoloNR, NierenbergAA, JensenJE, FavaM, RenshawPF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry, 2008; 63:1127–1134.
57.
. VidebechP.PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand, 2000; 101:11–20.
58.
. MaybergHS, BrannanSK, TekellJL, et al.Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry, 2000; 48:830–843.
59.
. DrevetsWC, BogersW, RaichleME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol, 2002; 12:527–544.
60.
. KennedySH, KonarskiJZ, SegalZV, et al.Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry, 2007; 164:778–788.
. SaltmarcheAE, NaeserMA, HoKF, HamblinMR, LimL. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: case series report. Photomed Laser Surg, 2017; 35:432–441.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
